Given the growing number of inquiries received about the possibility of injecting cannabis instrumentally, and given the dire consequences that could result from such act, the Spanish Observatory of Medicinal Cannabis (OECM) wants to clarify the following:
The currently available cannabis products are prepared to be administered sub-lingual or orally through the use of oils or capsules, rectally via suppositories, inhaled by vaporizers or through the skin for topical use with creams or oils. NONE of the medicinal cannabis products that we have at our disposal have been designed to be administered by means other than those exposed.
For a product to be “injected,” either subcutaneously, intramuscular, intravenously or “instrumentally,” it must be designed taking into account fundamental pharmacological factors, such as the bio compatibility of the solvent used. Non-bio compatible solvents could trigger toxic reactions with unpredictable consequences.
Inject able products must also be sterile. Otherwise, the risk of bacteriological contamination is very high, which could lead to an infection in the surrounding tissues, which could trigger generalized sepsis that could put the patient’s life at risk.
The injection technique itself also involves significant risks when highly qualified health personnel do not perform it in invasive techniques. These procedures are usually supported by imaging techniques (such as MRI or ultrasound) that allow absolute control of the needle trajectory, and avoid complications such as the appearance of illnesses, perforation of nearby organs, injection of the product within a blood vessel or administration of the product outside the tumor, among others.
Another serious consequence would be the breakage of the tumor structure, which could allow the extrapolation of tumor cells into the bloodstream and other tissues, with the serious risk of causing the appearance of metastases in other organs.